Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $547,933.70 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Tolga Tanguler sold 1,510 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $547,933.70. Following the completion of the sale, the executive vice president owned 29,728 shares of the company’s stock, valued at approximately $10,787,399.36. The trade was a 4.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded down $3.10 during mid-day trading on Wednesday, reaching $366.86. The company’s stock had a trading volume of 1,250,033 shares, compared to its average volume of 1,593,122. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. The stock has a fifty day moving average of $423.39 and a two-hundred day moving average of $421.94. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The firm has a market capitalization of $48.47 billion, a PE ratio of 1,528.58 and a beta of 0.32.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Needham & Company reiterated a bullish outlook and forecasted strong price appreciation for ALNY, giving investors a counterpoint to bearish views and providing potential support for the stock. Needham Bullish Forecast
• Positive Sentiment: Alnylam presented at the J.P. Morgan Healthcare Conference (transcript available) — management used the forum to outline development priorities and the Alnylam 2030 growth plan, keeping the company in front of institutional investors. JPM Presentation Transcript
• Neutral Sentiment: Analysis pieces are digesting the Alnylam 2030 plan and new 2026 guidance; valuation write-ups provide scenarios but do not change fundamentals immediately. These pieces are useful for longer-term investors assessing the plan vs. current multiples. Valuation After 2030 Plan
• Neutral Sentiment: CEO interviews and conference coverage (video/interview links) elaborate on development goals and timelines; useful for due diligence but contain no immediate new financials. CEO Interview
• Neutral Sentiment: Industry roundups from JPM/BioWorld reference Alnylam within broader biopharma Q4 revenue and guidance commentary — helpful context but not company-specific catalysts. Bioworld JPM Coverage
• Neutral Sentiment: Reported short-interest data appears anomalous (shows zero shares and NaN changes), so it should not be treated as signal until corrected by exchanges. No link (data issue)
• Negative Sentiment: Insider selling: CEO Yvonne Greenstreet and multiple EVPs sold shares on Jan 12–13 (CEO sale ~9,577 shares; several EVPs sold 1,510–2,780 shares each). Collectively these disclosed sales totaled roughly $7M, which markets often view as a near-term negative signal even if sales are for personal/diversification reasons. CEO SEC Filing
• Negative Sentiment: Bank of America published a pessimistic price forecast for ALNY, which can weigh on sentiment among institutional and retail investors. BofA Pessimistic Forecast
• Negative Sentiment: News coverage highlighted a sharp intraday sell-off (article noting ~9% drop) after the company unveiled ambitious 2026 guidance and its Alnylam 2030 plan — the market appears to be re-pricing risk around execution and near-term guidance. Coverage of the Sell-off

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Raymond James Financial reissued an “outperform” rating and set a $472.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday. Truist Financial dropped their price objective on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Needham & Company LLC increased their price objective on Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the company a “buy” rating in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Royal Bank Of Canada lifted their price target on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a research report on Friday, September 19th. Twenty-two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $490.96.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. Groupama Asset Managment raised its stake in Alnylam Pharmaceuticals by 160.4% in the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after buying an additional 2,483,697 shares in the last quarter. Norges Bank acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at about $662,837,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Alnylam Pharmaceuticals by 698.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock worth $618,158,000 after purchasing an additional 1,185,909 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in Alnylam Pharmaceuticals during the 3rd quarter worth $369,943,000. Finally, Holocene Advisors LP purchased a new position in Alnylam Pharmaceuticals during the second quarter worth about $194,616,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.